← Back

Cuorips Inc.

Cuorips Inc. is a biotechnology company involved in the research, development, manufacturing, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets. It also offers cellular and tissue-based products, cell processing products, contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. It was incorporated in 2017 and is headquartered in Tokyo, Japan.

Price · split & dividend adjusted
News & notes moving 4894.JP
4894.JP▲

Microwave Chemical develops open-space microwave technology; Keyence and Capcom surge on strong earnings

Among notable morning movers, Microwave Chemical announced it has developed microwave technology and equipment usable in open spaces and filed a patent application, sending the stock sharply higher on a rebound. Fruta Fruta partnered with Sumitani to launch full-scale cross-border e-commerce in China and opened a Tmall store. Qualips received approval for the insurance reimbursement price of its iPS cell-derived cardiomyocyte sheet and revised its operating loss forecast for the fiscal year ending March 2027 upward from 1.43 billion yen to 1.03 billion yen. Keyence reported first-quarter operating profit of 187.1 billion yen, up 44.7 percent year-on-year, beating consensus by about 30 billion yen, and the stock surged. Capcom posted first-quarter operating profit of 41.1 billion yen, a 66.9 percent increase from a year earlier, exceeding market expectations by roughly 12 billion yen, and extended sharp gains. Shimano saw a rapid recovery with April-to-June operating profit of 16.8 billion yen, up 40.6 percent year-on-year, and raised its full-year ordinary profit forecast from 53.3 billion yen to 56 billion yen. Komeri reported first-quarter operating profit of 10.9 billion yen, an 8.8 percent rise year-on-year, showing steady progress, and also announced a share buyback. Prestige International posted first-quarter operating profit of 2.27 billion yen, up 17.4 percent year-on-year, maintaining solid momentum, and its share buyback and commemorative shareholder benefits were also well received.
4290.JP · Capital · Positive Q1 operating profit up 17.4% YoY, share buyback and shareholder benefits well received.
4894.JP · Regulation · Positive Cuorips received approval for insurance reimbursement price of its iPS cell-derived cardiomyocyte sheet.
6861.JP · Capital · Positive Keyence reported Q1 operating profit up 44.7% YoY, beating consensus by ~30 billion yen.
7309.JP · Capital · Positive April-June operating profit up 40.6% YoY, raised full-year ordinary profit forecast.
8218.JP · Capital · Positive Reported 8.8% rise in Q1 operating profit and announced share buyback.
9227.JP · Technology · Positive Developed microwave technology usable in open spaces and filed patent application.
Read original ↗
フィスコ·68dRead more →